Patents Assigned to EntreMed, Inc.
-
Publication number: 20140056848Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof.Type: ApplicationFiled: March 8, 2013Publication date: February 27, 2014Applicant: ENTREMED, INC.Inventors: Tak Wah Mak, Gordon Stuart Duncan
-
Patent number: 8399440Abstract: The present invention relates a composition for treating rheumatic diseases. The composition comprises a compound having the formula wherein Ra is selected from —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CCCH3, —CHCH—CH3, or CH2—CHCH2; and one or more anti-rheumatic agents. A method of using the composition for treating rheumatic diseases in humans and animals is also disclosed.Type: GrantFiled: March 20, 2007Date of Patent: March 19, 2013Assignee: EntreMed, Inc.Inventors: William E. Fogler, Stacy M. Plum, Carolyn F. Sidor
-
Patent number: 8158612Abstract: Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.Type: GrantFiled: December 22, 2008Date of Patent: April 17, 2012Assignee: EntreMed, Inc.Inventors: Gregory E. Agoston, Jamshed H. Shah, Lita Suwandi, Theresa M. LaVallee, Anthony M. Treston
-
Publication number: 20090105205Abstract: Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.Type: ApplicationFiled: December 22, 2008Publication date: April 23, 2009Applicant: ENTREMED, INC.Inventors: Gregory E. Agoston, Jamshed H. Shah, Lita Suwandi, Theresa M. LaVallee, Anthony M. Treston
-
Patent number: 7498322Abstract: Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.Type: GrantFiled: March 11, 2005Date of Patent: March 3, 2009Assignee: EntreMed, Inc.Inventors: Gregory E. Agoston, Jamshed H. Shah, Lita Suwandi, Theresa M. LaVallee, Anthony M. Treston
-
Patent number: 7371741Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.Type: GrantFiled: May 28, 2004Date of Patent: May 13, 2008Assignee: EntreMed, Inc.Inventors: Gregory E. Agoston, Theresa M. LaVallee, Victor S. Pribluda, Jamshed H. Shah, Anthony M. Treston
-
Patent number: 7235540Abstract: 2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.Type: GrantFiled: September 26, 2005Date of Patent: June 26, 2007Assignee: EntreMed, Inc.Inventors: Gregory E. Agoston, Jamshed H. Shah, Anthony M. Treston
-
Patent number: 7135581Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.Type: GrantFiled: August 24, 2001Date of Patent: November 14, 2006Assignee: Entremed, Inc.Inventors: Gregory E. Agoston, Jamshed H. Shah, Kimberly A. Hunsucker, Victor S. Pribluda, Theresa M. LaVallee, Shawn J. Green, Christopher J. Herbstritt, Xiaoguo H. Zhan, Anthony M. Treston
-
Patent number: 6805865Abstract: Compositions and methods effective for eliciting an immune response for inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of a growth factor in a pharmaceutically acceptable carrier. The preferred growth factors comprise basic fibroblast growth factor and vascular endothelial growth factor. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to elicit an- immune response. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly where uncontrolled cell proliferation is influenced by the presence of growth factors.Type: GrantFiled: March 11, 1999Date of Patent: October 19, 2004Assignee: EntreMed, Inc.Inventors: John W. Holaday, Antonio Ruiz, John Madsen, Stacy M. Plum
-
Patent number: 6734163Abstract: Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.Type: GrantFiled: January 22, 2001Date of Patent: May 11, 2004Assignee: EntreMed, Inc.Inventors: Adonia E. Papathanassiu, Shawn J. Green
-
Patent number: 6723536Abstract: The present invention provides a method for recombinant production, recovery and purification of angiostatin protein. This method may be employed for large scale recovery and purification of recombinantly-produced angiostatin protein.Type: GrantFiled: October 18, 2001Date of Patent: April 20, 2004Assignee: EntreMed, Inc.Inventors: John Madsen, Hong Liang, Kim Lee Sim, Xinhua Zhou, Amy Chang-Murad, Renee J. Boerner, Lourdes L. Bermejo, Firoz R. Mistry, Jeffrey L. Schrimsher, Scot R. Shepard, Jeremy Johnston
-
Patent number: 6605622Abstract: The present invention provides compounds that are useful for inhibiting the proliferation of fungi. The compounds are estrogenic derivatives, such as 2ME2, or anti-estrogenic compounds. The compounds may be used for treating infections of fungi in humans and animals, or to prevent or inhibit the growth of fungi on any surface.Type: GrantFiled: May 25, 2001Date of Patent: August 12, 2003Assignee: EntreMed, Inc.Inventors: Shawn J. Green, Adonia Papathanassiu
-
Patent number: 6593291Abstract: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise naturally occurring, or synthetic proteins, peptides, or protein fragments capable of binding to components of the blood coagulation pathway. The compositions may be administered using a pharmaceutically acceptable carrier. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized metastasized tumors is useful for preventing the growth or expansion of such tumors.Type: GrantFiled: October 14, 1999Date of Patent: July 15, 2003Assignee: EntreMed, Inc.Inventors: Shawn J. Green, Adonia E. Papathanassiu
-
Patent number: 6544947Abstract: Compositions and methods for regulating angiogenic activity wherein the compositions comprise cancer markers including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.Type: GrantFiled: July 17, 2001Date of Patent: April 8, 2003Assignee: EntreMed, Inc.Inventors: John W. Holaday, Anne H. Fortier
-
Patent number: 6518298Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.Type: GrantFiled: February 20, 2001Date of Patent: February 11, 2003Assignee: Entremed, Inc.Inventors: Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Robert J. D'Amato
-
Patent number: 6413513Abstract: Compositions and methods for regulating angiogenic activity wherein the compositions comprise cancer markers including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.Type: GrantFiled: October 6, 1999Date of Patent: July 2, 2002Assignee: Entremed, Inc.Inventors: John W. Holaday, Anne H. Fortier
-
Patent number: 6239123Abstract: The present invention provides compounds that are useful for inhibiting the proliferation of fungi. The compounds are estrogenic derivatives, such as 2ME2, or anti-estrogenic compounds. The compounds may be used for treating infections of fungi in humans and animals, or to prevent or inhibit the growth of fungi on any surface.Type: GrantFiled: August 10, 1999Date of Patent: May 29, 2001Assignee: Entremed, Inc.Inventor: Shawn J. Green
-
Patent number: 6224902Abstract: The present invention relates to immunoreactive vaccine compositions for immunizing humans or animals against sterols, such as cholesterol and its derivatives, and their use in methods for reducing the serum cholesterol levels of the immunized individuals and to retard or reduce the severity of artherosclerosis or artherosclerosis plaques caused by ingestion of dietary cholesterol.Type: GrantFiled: February 13, 1998Date of Patent: May 1, 2001Assignee: EntreMed, Inc.Inventors: Carl R. Alving, Julie Kenner, Glenn M. Swartz, Jr., John W. Madsen
-
Patent number: 6201104Abstract: The present invention relates to peptides and proteins such as receptors that bind angiogenesis-related proteins ANGIOSTATIN™ protein or ENDOSTATIN™ protein. Peptides and proteins of the present invention can be isolated from body fluids including blood or urine, or can be synthesized by recombinant, enzymatic or chemical methods. The peptides are particularly important for identifying receptors of angiogenesis-related proteins, as well as for identifying other proteins that regulate, transport and otherwise interact with angiogenesis-related proteins.Type: GrantFiled: December 4, 1998Date of Patent: March 13, 2001Assignee: EntreMed, Inc.Inventors: Nicholas J. MacDonald, Kim Lee Sim
-
Patent number: 6090617Abstract: An improved electrode for use in generating an electrical field in a saline solution is provided. In particular, a continuous crystalline metal nitride coated electrode is provided for use in a variety of saline solution applications, such as in an electrophoresis device for separating proteins or nucleic acids or an electroporation apparatus for the encapsulation of biologically-active substances in various cell populations. A method and apparatus are provided for the encapsulation of biologically-active substances in red blood cells, characterized by an optionally automated, continuous-flow, self-contained electroporation system which allows withdrawal of blood from a patient, separation of red blood cells, encapsulation of a biologically-active substances in the cells, and optional recombination of blood plasma and the modified red blood cells thereby producing blood with modified biological characteristics.Type: GrantFiled: December 5, 1996Date of Patent: July 18, 2000Assignee: EntreMed, Inc.Inventor: Peter Meserol